Drug intelligence / Profile preview

BT8825

Development stage: Preclinical
Lead developer: BioArctic
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

BT8825 is a research-stage monoclonal antibody program being developed by BioArctic in collaboration with Novartis for the treatment of neurodegenerative diseases. The program utilizes BioArctic's proprietary BrainTransporter™ technology, which leverages transferrin receptor (TfR)-mediated active transport to facilitate the delivery of therapeutic antibodies across the blood-brain barrier (BBB). This platform is designed to significantly increase brain exposure—up to 70-fold compared to conventional antibodies. BT8825 combines this transport mechanism with a proprietary Novartis antibody directed against an undisclosed molecular target associated with neurodegeneration. As of August 2025, the program is in the early research and preclinical stages.

Targets

TFRC (Transferrin Receptor)

Beyond the preview

Go deeper on BT8825.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BT8825.

Explore the full profile